Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy

• Published in: Journal of thrombosis and thrombolysis 2011-11, Vol.32 (4), p.467-473
• Main Authors: Kwon, Aerin, Jo, Sang-Ho, Im, Hyoung-June, Jo, Yun-A, Park, Ji-Young, Kang, Hee Jung, Kim, Han-Sung, Cho, Hyoun Chan, Lee, Young Kyung
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Anticoagulants - therapeutic use; Aryl Hydrocarbon Hydroxylases - genetics; Cardiology; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gene Frequency; Genotype; Hematology; Humans; International Normalized Ratio; Korea; Male; Medicine; Medicine & Public Health; Middle Aged; Mixed Function Oxygenases - genetics; Pharmacogenetics - methods; Polymorphism, Genetic; Vitamin K Epoxide Reductases; Warfarin - pharmacology; Warfarin - therapeutic use
• ISSN: 0929-5305; 1573-742X
• DOI: 10.1007/s11239-011-0616-3

During warfarin treatment, determining the optimal dose and maintaining the target PT-INR are challenging. Increasing evidence supports the theory that genotypic polymorphisms influence an individual’s warfarin dose requirement. In this study, we evaluated allele frequencies and effects of CYP2C9 and VKORC1 on warfarin response during initial anticoagulation therapy in Korean patients. We enrolled patients who had initiated warfarin therapy and undergone PT-INR testing at least three times within the first month of anticoagulation therapy. All the participating patients were tested for the detection of CYP2C9 *3 (c.1075A>C) and VKORC1 -1639G>A. A melting-curve analysis after real-time PCR was performed using CYP2C9*3 and VK1639 genotyping kits (Idaho Technology, US). A total of 37 patients were enrolled in this study. CYP2C9 *1/*1 (87%) and VKORC1 -1639AA genotypes (89%) were predominant in Korea. The CYP2C9 *3 and VKORC1 -1639G alleles were found in five (13%) and four patients (11%), respectively. Patients with the CYP2C9 *3 allele received a lower warfarin dose ( P  = 0.018) and tended to show more rapid PT-INR increase than CYP2C9 *1/*1 genotype. Patients with the VKORC1 -1639G allele nonsignificantly received higher warfarin dose than those without. The CYP2C9 *3 and VKORC1 -1639G alleles influenced warfarin response during the first month of anticoagulation therapy. Considering these results, CYP2C9 and VKORC1 genotyping can be an useful tool to estimate initial warfarin dose and frequency of PT-INR monitoring during the first month of anticoagulation therapy.